Takeda Pharmaceutical (TYO:4502) and Portal Instruments said today that the pair inked a collaboration to develop and commercialize Portal’s needle-free drug delivery device with Takeda’s biologic medicines.
The first development program is slated to combine Takeda’s monoclonal antibody for adults with moderately- to severely-active ulcerative colitis or Crohn’s disease with Portal’s technology. The investigational therapy is currently administered through intravenous infusion, according to Takeda.
Get the full story at our sister site, Drug Delivery Business News.
The post Takeda, Portal Instruments ink $100m deal to combine biologics and needle-free drug delivery appeared first on MassDevice.